MedTrace Logo

Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma

NCT02031419 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 174

Last updated 2024-01-18

No results posted yet for this study

Summary

First study, at multiple clinical centers, exploring the effects of different combinations of compounds (CC-122, CC-223 ,CC-292 and rituximab) to treat Diffuse Large B Cell Lymphoma (DLBCL) and Follicular Lymphoma

Conditions

  • Lymphoma, Large B-Cell, Diffuse

Interventions

DRUG

CC-122

2mg or 3 mg administered orally once daily

DRUG

CC-223

20mg or 30mg administered orally once daily.

DRUG

Rituximab

375 mg/m2 administered intravenously once every 28 days

DRUG

CC-122

2mg or 3mg administered orally once daily.

DRUG

CC-292

500 mg twice a day administered orally.

DRUG

Rituximab

375 mg/m2 administered intravenously once every 28 days

DRUG

CC-223

20mg or 30mg per day administered orally daily.

DRUG

CC-292

500 mg twice a day administered orally.

DRUG

Rituximab

375 mg/m2 administered intravenously once every 28 days

Sponsors & Collaborators

  • Celgene

    lead INDUSTRY

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-12-18
Primary Completion
2023-12-12
Completion
2023-12-12

Countries

  • United States
  • Canada
  • France
  • Italy

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02031419 on ClinicalTrials.gov